In vivo animal model of human leukemia

Abstract

The present invention provides a process for making an in vivo model of human leukemia. The process includes the steps of: pre-conditioning an immunodeficient rodent by administering to the rodent a sub-lethal dose of irradiation and injecting the rodent with an effective pre-conditioning amount of human fetal cord blood mononuclear cells; maintaining the rodent for from about 5 to 10 days; and injecting the rodent with an effective engrafting amount of primary human leukemia cells. An in vivo and in vitro model of human leukemia are also provided.

Description

[0001] Funds used to support some of the studies reported herein were provided by the National Institutes of Health (NIH DK40218). The United States Government may, therefore, have certain rights in the invention disclosed herein.TECHNICAL FIELD OF THE INVENTION [0002] The field of this invention is leukemia. More particularly, this invention pertains to models of human leukemia including an in vivo rodent model of human leukemia. BACKGROUND OF THE INVENTION [0003] T-cell acute lymphoblastic leukemia (T-ALL) comprises −20% of ALL (Kersey J H., Blood 1997; 90: 4243-4251), with ALL being the most common type of cancer in children. A better understanding of the biology of T-ALL at the molecular level would facilitate the development of selective therapy that exploits specific biological properties of the leukemia, thereby improving the outlook for this disease. Even though a number of leukemia cell lines of T-cell origin have been established from patients (Gjerset R, et al., Cancer Re...

AI Technical Summary

Benefits of technology

The present invention provides a process for making an in vivo model of human leukemia in rodents, which involves pre-conditioning the rodent by irradiation and injecting it with mononuclear cells derived from human fetal cord blood. The rodent is then maintained for a certain period of time before being injected with primary human leukemia cells. The invention also provides an immunodeficient rodent that has engrafted human leukemia cells and can be used for screening anti-leukemic drugs. The engrafted leukemia cells can be found in the bone marrow and spleen of the rodent. The invention allows for the study of leukemia at the molecular level and the testing of drugs that can target the disease.

Problems solved by technology

Even though a number of leukemia cell lines of T-cell origin have been established from patients (Gjerset R, et al., Cancer Res 1990; 50: 10-14; Smith S D, et al., Blood 1978; 52: 712-718; Lange B, et al., Blood 1987; 70: 192-199; and Smith S D, et al., Cancer Res 1984; 44: 5657-5660), difficulty in maintaining primary cultures of leukemia cells from patients has impeded study of the development of the disease.

Images